Asuragen Press Releases
06-23-08Asuragen to present study results on differentially expressed microRNA biomarkers in pancreatic FNA and FFPE specimens, which can distinguish benign from malignant tissues at the Annual Meeting of the European Pancreatic Club in Poland
05-14-08Asuragen Launches RNARetain™, as a CE-marked In-Vitro Diagnostic Device
04-23-08Asuragen Launches Signature® LTx (Leukemia Translocation Panel) Globally
04-23-08Asuragen Launches The First Validated microRNA Diagnostic Assay
03-31-08Asuragen launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics
03-25-08Yale and Asuragen Scientists Show that a microRNA Can Reduce Lung Cancer Growth
01-03-08Asuragen to Present at the JPMorgan 26th Annual Healthcare Conference
12-19-07Asuragen introduces Four New microRNA Services
12-10-07Asuragen, Inc. Raises $18.5 Million in Series B Financing
10-29-07 Xenomics Announces License with Asuragen for NPM1 Leukemia Diagnostics
10-23-07 Asuragen Enters Oncology Collaboration with Merck to Develop Pharmacogenomic Tests
10-08-07 Asuragen Licenses Roche’s Real-time Quantitative PCR Technology for Clinical Gene Expression Profilinge
08-29-07 Asuragen to Present at the Thomas Weisel Partners Healthcare Conference
08-02-07 Asuragen Launches Powerful New miRNA Analysis Tool
05-29-07 Asuragen, Inc. to provide GLP laboratory testing services to aid a Leading Biotechnology Organization
04-16-07 Agendia accesses Asuragen’s proprietary pre-analytical solution for tissue preservation...
01-10-07 Asuragen Becomes the First Certified Service Provider for Illumina Gene Expression Profiling
01-09-07 Asuragen Enters Into Licensing Agreement with Yale for Therapeutic Use of let-7 miRNA
01-03-07 Asuragen to Present at the JPMorgan 25th Annual Healthcare Conference
12-14-06 Asuragen, Inc. Achieves ISO 13485 and ISO 9001 Certification
09-11-06 Asuragen Joins Industry Leaders in Completion of the FDA MAQC Project
08-16-06 Asuragen’s microRNA Expression Profiling Service Offers Sanger miRBase 8.0 Plus New Proprietary Content
07-27-06 Asuragen Announces MicroRNA Co-Exclusive License Agreement with Max Planck Society
07-26-06 Asuragen Secures MicroRNA Licensing Agreement with Rockefeller University
06-01-06 Newly Launched Asuragen Closes Series A Funding of $49 Million